184 related articles for article (PubMed ID: 28186757)
21. Design, synthesis and biological activity of 3-oxoamino-benzenesulfonamides as selective and reversible LSD1 inhibitors.
Xi J; Xu S; Wu L; Ma T; Liu R; Liu YC; Deng D; Gu Y; Zhou J; Lan F; Zha X
Bioorg Chem; 2017 Jun; 72():182-189. PubMed ID: 28460360
[TBL] [Abstract][Full Text] [Related]
22. Lysine-Specific Demethylase 1 Inhibitors: A Comprehensive Review Utilizing Computer-Aided Drug Design Technologies.
Han D; Lu J; Fan B; Lu W; Xue Y; Wang M; Liu T; Cui S; Gao Q; Duan Y; Xu Y
Molecules; 2024 Jan; 29(2):. PubMed ID: 38276629
[TBL] [Abstract][Full Text] [Related]
23. Discovery of resveratrol derivatives as novel LSD1 inhibitors: Design, synthesis and their biological evaluation.
Duan YC; Guan YY; Zhai XY; Ding LN; Qin WP; Shen DD; Liu XQ; Sun XD; Zheng YC; Liu HM
Eur J Med Chem; 2017 Jan; 126():246-258. PubMed ID: 27888721
[TBL] [Abstract][Full Text] [Related]
24. Annual review of lysine-specific demethylase 1 (LSD1/KDM1A) inhibitors in 2021.
Song Y; Zhang H; Yang X; Shi Y; Yu B
Eur J Med Chem; 2022 Jan; 228():114042. PubMed ID: 34915312
[TBL] [Abstract][Full Text] [Related]
25. Pharmacological Inhibition of the Histone Lysine Demethylase KDM1A Suppresses the Growth of Multiple Acute Myeloid Leukemia Subtypes.
McGrath JP; Williamson KE; Balasubramanian S; Odate S; Arora S; Hatton C; Edwards TM; O'Brien T; Magnuson S; Stokoe D; Daniels DL; Bryant BM; Trojer P
Cancer Res; 2016 Apr; 76(7):1975-88. PubMed ID: 26837761
[TBL] [Abstract][Full Text] [Related]
26. CD86 expression as a surrogate cellular biomarker for pharmacological inhibition of the histone demethylase lysine-specific demethylase 1.
Lynch JT; Cockerill MJ; Hitchin JR; Wiseman DH; Somervaille TC
Anal Biochem; 2013 Nov; 442(1):104-6. PubMed ID: 23911524
[TBL] [Abstract][Full Text] [Related]
27. Development of the triazole-fused pyrimidine derivatives as highly potent and reversible inhibitors of histone lysine specific demethylase 1 (LSD1/KDM1A).
Li Z; Ding L; Li Z; Wang Z; Suo F; Shen D; Zhao T; Sun X; Wang J; Liu Y; Ma L; Zhao B; Geng P; Yu B; Zheng Y; Liu H
Acta Pharm Sin B; 2019 Jul; 9(4):794-808. PubMed ID: 31384539
[TBL] [Abstract][Full Text] [Related]
28. Design and synthesis of tranylcypromine derivatives as novel LSD1/HDACs dual inhibitors for cancer treatment.
Duan YC; Ma YC; Qin WP; Ding LN; Zheng YC; Zhu YL; Zhai XY; Yang J; Ma CY; Guan YY
Eur J Med Chem; 2017 Nov; 140():392-402. PubMed ID: 28987602
[TBL] [Abstract][Full Text] [Related]
29. Identification of cell-active lysine specific demethylase 1-selective inhibitors.
Ueda R; Suzuki T; Mino K; Tsumoto H; Nakagawa H; Hasegawa M; Sasaki R; Mizukami T; Miyata N
J Am Chem Soc; 2009 Dec; 131(48):17536-7. PubMed ID: 19950987
[TBL] [Abstract][Full Text] [Related]
30. Optimization of 5-arylidene barbiturates as potent, selective, reversible LSD1 inhibitors for the treatment of acute promyelocytic leukemia.
Xu S; Zhou C; Liu R; Zhu Q; Xu Y; Lan F; Zha X
Bioorg Med Chem; 2018 Sep; 26(17):4871-4880. PubMed ID: 30153955
[TBL] [Abstract][Full Text] [Related]
31. Histone H3 peptides incorporating modified lysine residues as lysine-specific demethylase 1 inhibitors.
Kakizawa T; Ota Y; Itoh Y; Suzuki T
Bioorg Med Chem Lett; 2018 Jan; 28(2):167-169. PubMed ID: 29198865
[TBL] [Abstract][Full Text] [Related]
32. A comprehensive review of lysine-specific demethylase 1 and its roles in cancer.
Hosseini A; Minucci S
Epigenomics; 2017 Aug; 9(8):1123-1142. PubMed ID: 28699367
[TBL] [Abstract][Full Text] [Related]
33. Annual review of LSD1/KDM1A inhibitors in 2020.
Fu DJ; Li J; Yu B
Eur J Med Chem; 2021 Mar; 214():113254. PubMed ID: 33581557
[TBL] [Abstract][Full Text] [Related]
34. High-throughput virtual screening identifies novel N'-(1-phenylethylidene)-benzohydrazides as potent, specific, and reversible LSD1 inhibitors.
Sorna V; Theisen ER; Stephens B; Warner SL; Bearss DJ; Vankayalapati H; Sharma S
J Med Chem; 2013 Dec; 56(23):9496-508. PubMed ID: 24237195
[TBL] [Abstract][Full Text] [Related]
35. Molecular docking, 3D-QSAR, and molecular dynamics simulations of thieno[3,2-b]pyrrole derivatives against anticancer targets of KDM1A/LSD1.
Zhang X; Yan J; Wang H; Wang Y; Wang J; Zhao D
J Biomol Struct Dyn; 2021 Mar; 39(4):1189-1202. PubMed ID: 32036765
[TBL] [Abstract][Full Text] [Related]
36. Discovery and synthesis of novel indole derivatives-containing 3-methylenedihydrofuran-2(3H)-one as irreversible LSD1 inhibitors.
Liu HM; Suo FZ; Li XB; You YH; Lv CT; Zheng CX; Zhang GC; Liu YJ; Kang WT; Zheng YC; Xu HW
Eur J Med Chem; 2019 Aug; 175():357-372. PubMed ID: 31096156
[TBL] [Abstract][Full Text] [Related]
37. Development of 5-hydroxypyrazole derivatives as reversible inhibitors of lysine specific demethylase 1.
Mould DP; Bremberg U; Jordan AM; Geitmann M; Maiques-Diaz A; McGonagle AE; Small HF; Somervaille TCP; Ogilvie D
Bioorg Med Chem Lett; 2017 Jul; 27(14):3190-3195. PubMed ID: 28545974
[TBL] [Abstract][Full Text] [Related]
38. Capsaicin: A "hot" KDM1A/LSD1 inhibitor from peppers.
Jia G; Cang S; Ma P; Song Z
Bioorg Chem; 2020 Oct; 103():104161. PubMed ID: 32889380
[TBL] [Abstract][Full Text] [Related]
39. Structure-based design and discovery of potent and selective lysine-specific demethylase 1 (LSD1) inhibitors.
Nie Z; Shi L; Lai C; Severin C; Xu J; Del Rosario JR; Stansfield RK; Cho RW; Kanouni T; Veal JM; Stafford JA; Chen YK
Bioorg Med Chem Lett; 2019 Jan; 29(1):103-106. PubMed ID: 30409536
[TBL] [Abstract][Full Text] [Related]
40. Ligand-based design, synthesis and biological evaluation of xanthine derivatives as LSD1/KDM1A inhibitors.
Ma QS; Yao Y; Zheng YC; Feng S; Chang J; Yu B; Liu HM
Eur J Med Chem; 2019 Jan; 162():555-567. PubMed ID: 30472603
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
